Merck Beats Q1 EPS Estimates, Raises Full-Year Guidance, and Highlights Strong Pipeline Progress
MRK sits 54% above its 52-week low of $73.31.
Summary
Merck reported better-than-expected Q1 adjusted earnings and raised its full-year sales and EPS guidance, driven by strong product performance and significant pipeline advancements, including new drug approvals and a strategic acquisition.
Key Events · Earnings and Guidance · MRK
-
Strong Q1 Financials
Reported Q1 adjusted loss per share of $1.28, exceeding analyst estimates, with total sales growing 5% to $16.3 billion, despite a $3.62 per share charge for the Cidara acquisition.
-
Raised Full-Year Guidance
Increased the midpoint of its 2026 sales outlook to $65.8-$67.0 billion and non-GAAP EPS guidance to $5.04-$5.16, reflecting a positive outlook.
-
Key Regulatory Approvals
Received U.S. FDA approval for IDVYNSO, a new oral HIV-1 treatment, and achieved multiple oncology regulatory milestones for KEYTRUDA.
-
Pipeline Progress
Announced positive Phase 3 results for enlicitide in LDL-C and advanced WINREVAIR for pulmonary hypertension, alongside other clinical developments.
Analysis · MRK · Life Sciences
Merck reported a Q1 adjusted loss per share of $1.28, which was better than analyst estimates, despite including a significant one-time charge of $3.62 per share related to the acquisition of Cidara Therapeutics. Total worldwide sales grew 5% to $16.3 billion, driven by strong performance in oncology, animal health, and new product launches. The company raised the midpoint of its full-year 2026 sales guidance to $65.8 billion - $67.0 billion and its non-GAAP EPS guidance to $5.04 - $5.16, signaling confidence in its operational performance and pipeline. Key pipeline advancements include the FDA approval of IDVYNSO for HIV-1, multiple regulatory milestones for KEYTRUDA in oncology, positive Phase 3 results for enlicitide in LDL-C, and advancing WINREVAIR for pulmonary hypertension. The recently announced acquisition of Terns Pharmaceuticals, expected to close in May, will further expand the hematology pipeline with TERN-701.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 36.7% of the 976 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.68%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRK was trading at $113.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $274B. The 52-week trading range was $73.31 to $125.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.